Head of Regulatory Affairs Regulatory strategy development, submission management, and global market access for medical device organizations. Table of Contents Regulatory Strategy Workflow FDA Submission Workflow EU MDR Submission Workflow Global Market Access Workflow Regulatory Intelligence Workflow Decision Frameworks Tools and References Regulatory Strategy Workflow Develop regulatory strategy aligned with business objectives and product characteristics. Workflow: New Product Regulatory Strategy Gather product information: Intended use and indications Device classification (risk level) Technology platform Target markets and timeline Identify applicable regulations per target market: FDA (US): 21 CFR Part 820, 510(k)/PMA/De Novo EU: MDR 2017/745, Notified Body requirements Other markets: Health Canada, PMDA, NMPA, TGA Determine optimal regulatory pathway: Compare submission types (510(k) vs De Novo vs PMA) Assess predicate device availability Evaluate clinical evidence requirements Develop regulatory timeline with milestones Estimate resource requirements and budget Identify regulatory risks and mitigation strategies Obtain stakeholder alignment and approval Validation: Strategy document approved; timeline accepted; resources allocated Regulatory Pathway Selection Matrix Factor 510(k) De Novo PMA Predicate Available Yes No N/A Risk Level Low-Moderate Low-Moderate High Clinical Data Usually not required May be required Required Review Time 90 days (MDUFA) 150 days 180 days User Fee ~$22K (2024) ~$135K ~$440K Best For Me-too devices Novel low-risk High-risk, novel Regulatory Strategy Document Template REGULATORY STRATEGY Product: [Name] Version: [X.X] Date: [Date] 1. PRODUCT OVERVIEW - Intended use: [Statement] - Device classification: [Class I/II/III] - Technology: [Description] 2. TARGET MARKETS | Market | Priority | Timeline | |--------|----------|----------| | USA | 1 | Q1 20XX | | EU | 2 | Q2 20XX | 3. REGULATORY PATHWAY - FDA: [510(k) / De Novo / PMA] - EU: [Class] via [Conformity route] - Rationale: [Justification] 4. CLINICAL EVIDENCE STRATEGY - Requirements: [Summary] - Approach: [Literature / Study / Both] 5. TIMELINE AND MILESTONES [Gantt or milestone table] 6. RISKS AND MITIGATION | Risk | Probability | Impact | Mitigation | |------|-------------|--------|------------| 7. RESOURCE REQUIREMENTS - Budget: $[Amount] - Personnel: [FTEs] - External support: [Consultants, CRO] FDA Submission Workflow Prepare and submit FDA regulatory applications. Workflow: 510(k) Submission Confirm 510(k) pathway suitability: Predicate device identified Substantial equivalence supportable No new intended use or technology concerns Schedule and conduct Pre-Submission (Q-Sub) meeting if needed Compile submission package: Cover letter and administrative information Device description and intended use Substantial equivalence comparison Performance testing data Biocompatibility (if patient contact) Software documentation (if applicable) Labeling and IFU Conduct internal review and quality check Prepare eCopy per FDA format requirements Submit via FDA ESG portal with user fee payment Monitor MDUFA clock and respond to AI/RTA requests Validation: Submission accepted; MDUFA date received; tracking system updated Workflow: PMA Submission Confirm PMA pathway: Class III device or no predicate Clinical data strategy defined Complete IDE clinical study if required: IDE approval Clinical protocol execution Study report completion Conduct Pre-Submission meeting Compile PMA submission: Administrative and device information Manufacturing information Nonclinical studies Clinical studies Labeling Submit original PMA application Address FDA questions and deficiencies Prepare for FDA facility inspection Validation: PMA approved; approval letter received; post-approval requirements documented FDA Submission Timeline Milestone 510(k) De Novo PMA Pre-Sub Meeting Day -90 Day -90 Day -120 Submission Day 0 Day 0 Day 0 RTA Review Day 15 Day 15 Day 45 Substantive Review Days 15-90 Days 15-150 Days 45-180 Decision Day 90 Day 150 Day 180 Common FDA Deficiencies Category Common Issues Prevention Substantial Equivalence Weak predicate comparison Strong SE argument upfront Performance Testing Incomplete test protocols Follow recognized standards Biocompatibility Missing endpoints ISO 10993 risk assessment Software Inadequate documentation IEC 62304 compliance Labeling Inconsistent claims Early labeling review See: references/fda-submission-guide.md EU MDR Submission Workflow Achieve CE marking under EU MDR 2017/745. Workflow: MDR Technical Documentation Confirm device classification per MDR Annex VIII Select conformity assessment route based on class: Class I: Self-declaration Class IIa/IIb: Notified Body involvement Class III: Full NB assessment Select and engage Notified Body (for Class IIa+) Compile Technical Documentation per Annex II: Device description and specifications Design and manufacturing information General Safety and Performance Requirements (GSPR) checklist Benefit-risk analysis and risk management Clinical evaluation per Annex XIV Post-market surveillance plan Establish and document QMS per ISO 13485 Submit application to Notified Body Address NB questions and coordinate audit Validation: CE certificate issued; Declaration of Conformity signed; EUDAMED registration complete MDR Classification Decision Tree Is the device active? │ Yes─┴─No │ │ ▼ ▼ Is it an Does it contact implant? the body? │ │ Yes─┴─No Yes─┴─No │ │ │ │ ▼ ▼ ▼ ▼ III IIb Check Class I contact (measuring/ type sterile if and applicable) duration Clinical Evidence Requirements by Class Class Clinical Requirement Documentation I Clinical evaluation (CE) CE report IIa CE with literature focus CE report + PMCF plan IIb CE with clinical data CE report + PMCF + clinical study (some) III CE with clinical investigation CE report + PMCF + clinical investigation Notified Body Selection Criteria Criterion Consideration Scope Device category expertise Capacity Availability and review timeline Experience Track record in your technology Geography Proximity for audits Cost Fee structure transparency Communication Responsiveness and clarity See: references/eu-mdr-submission-guide.md Global Market Access Workflow Coordinate regulatory approvals across international markets. Workflow: Multi-Market Submission Strategy Define target markets based on business priorities Sequence markets for efficient evidence leverage: Phase 1: FDA + EU (reference markets) Phase 2: Recognition markets (Canada, Australia) Phase 3: Major markets (Japan, China) Phase 4: Emerging markets Identify local requirements per market: Clinical data acceptability Local agent/representative needs Language and labeling requirements Develop master technical file with localization plan Establish in-country regulatory support Execute parallel or sequential submissions Track approvals and coordinate launches Validation: All target market approvals obtained; registration database updated Market Priority Matrix Market Size Complexity Recognition Priority USA Large High N/A 1 EU Large High N/A 1-2 Canada Medium Medium MDSAP 2 Australia Medium Low EU accepted 2 Japan Large High Local clinical 3 China Large Very High Local testing 3 Brazil Medium High GMP inspection 3-4 Documentation Efficiency Strategy Document Type Single Source Localization Required Technical file core Yes Format adaptation Risk management Yes None Clinical data Yes Bridging assessment QMS certificate Yes (ISO 13485) Market-specific audit Labeling Master label Translation, local requirements IFU Master content Translation, local symbols See: references/global-regulatory-pathways.md Regulatory Intelligence Workflow Monitor and respond to regulatory changes affecting product portfolio. Workflow: Regulatory Change Management Monitor regulatory sources: FDA Federal Register, guidance documents EU Official Journal, MDCG guidance Notified Body communications Industry associations (AdvaMed, MedTech Europe) Assess relevance to product portfolio Evaluate impact: Timeline to compliance Resource requirements Product changes needed Develop compliance action plan Communicate to affected stakeholders Implement required changes Document compliance status Validation: Compliance action plan approved; changes implemented on schedule Regulatory Monitoring Sources Source Type Frequency FDA Federal Register Regulations, guidance Daily FDA Device Database 510(k), PMA, recalls Weekly EU Official Journal MDR/IVDR updates Weekly MDCG Guidance EU implementation As published ISO/IEC Standards updates Quarterly Notified Body Audit findings, trends Per interaction Impact Assessment Template REGULATORY CHANGE IMPACT ASSESSMENT Change: [Description] Source: [Regulation/Guidance] Effective Date: [Date] Assessment Date: [Date] Assessed By: [Name] AFFECTED PRODUCTS | Product | Impact | Action Required | Timeline | |---------|--------|-----------------|----------| | [Name] | [H/M/L]| [Description] | [Date] | COMPLIANCE ACTIONS 1. [Action 1] - Owner: [Name] - Due: [Date] 2. [Action 2] - Owner: [Name] - Due: [Date] RESOURCE REQUIREMENTS - Budget: $[Amount] - Personnel: [Hours/FTEs] APPROVAL Regulatory: __ Date: _ Management: __ Date: _ Decision Frameworks Pathway Selection Decision Tree Is predicate device available? │ Yes─┴─No │ │ ▼ ▼ Is device Is risk level substantially Low-Moderate? equivalent? │ │ Yes─┴─No Yes─┴─No │ │ │ │ ▼ ▼ ▼ ▼ De Novo PMA 510(k) Consider required De Novo or PMA Pre-Submission Meeting Decision Factor Schedule Pre-Sub Skip Pre-Sub Novel Technology ✓ New Intended Use ✓ Complex Testing ✓ Uncertain Predicate ✓ Clinical Data Needed ✓ Well-established ✓ Clear Predicate ✓ Standard Testing ✓ Regulatory Escalation Criteria Situation Escalation Level Action Submission rejection VP Regulatory Root cause analysis, strategy revision Major deficiency Director Cross-functional response team Timeline at risk Management Resource reallocation review Regulatory change VP Regulatory Portfolio impact assessment Safety signal Executive Immediate containment and reporting Tools and References Scripts Tool Purpose Usage regulatory_tracker.py Track submission status and timelines python regulatory_tracker.py Regulatory Tracker Features: Track multiple submissions across markets Monitor status and target dates Identify overdue submissions Generate status reports References Document Content fda-submission-guide.md FDA pathways, requirements, review process eu-mdr-submission-guide.md MDR classification, technical documentation, clinical evidence global-regulatory-pathways.md Canada, Japan, China, Australia, Brazil requirements iso-regulatory-requirements.md ISO 13485, 14971, 10993, IEC 62304, 62366 requirements Key Performance Indicators KPI Target Calculation First-time approval rate
85% (Approved without major deficiency / Total submitted) × 100 On-time submission 90% (Submitted by target date / Total submissions) × 100 Review cycle compliance 95% (Responses within deadline / Total requests) × 100 Regulatory hold time <20% (Days on hold / Total review days) × 100